Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of M207 vs Intranasal Zolmitriptan in Healthy Volunteers
NCT04969497Phase 1Completed
- Sponsor
- Zosano Pharma
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZP-Triptan in migraine (6 arms), sponsored by Zosano Pharma. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 24 hours, Cmax at 24 hours and 1 more. Started Jun 2021; status: completed.
02
Drugs
ZP-Triptan
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04969497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04969497.